Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
174 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Kidney Transplant Rejection - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2016, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape. Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 10, 7, 12 and 2 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Kidney Transplant Rejection. Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology). - The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Kidney Transplant Rejection Overview 8 Therapeutics Development 9 Pipeline Products for Kidney Transplant Rejection - Overview 9 Pipeline Products for Kidney Transplant Rejection - Comparative Analysis 10 Kidney Transplant Rejection - Therapeutics under Development by Companies 11 Kidney Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 13 Kidney Transplant Rejection - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Kidney Transplant Rejection - Products under Development by Companies 17 Kidney Transplant Rejection - Products under Investigation by Universities/Institutes 19 Kidney Transplant Rejection - Companies Involved in Therapeutics Development 20 Alexion Pharmaceuticals Inc 20 Amgen Inc. 21 Amyndas Pharmaceuticals LLC 22 Angion Biomedica Corp. 23 Apellis Pharmaceuticals Inc 24 Astellas Pharma Inc. 25 Bio-inRen 26 Biogen Inc 27 Catalyst Biosciences, Inc. 28 Corline Biomedical AB 29 CSL Limited 30 Digna Biotech, S.L. 31 GlaxoSmithKline Plc 32 Grifols, S.A. 33 Hansa Medical AB 34 Kyowa Hakko Kirin Co., Ltd. 35 Mabtech Limited 36 Magnus Life Ltd 37 Noorik Biopharmaceuticals AG 38 Novartis AG 39 Opsona Therapeutics Limited 40 OSE Immunotherapeutics 41 Pharmicell Co., Ltd. 42 Pharming Group N.V. 43 Prolong Pharmaceuticals, LLC 44 Quark Pharmaceuticals, Inc. 45 Shire Plc 46 Tiziana Life Sciences Plc 47 Kidney Transplant Rejection - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Target 49 Assessment by Mechanism of Action 51 Assessment by Route of Administration 53 Assessment by Molecule Type 55 Drug Profiles 57 albumin (human) - Drug Profile 57 AMY-101 - Drug Profile 58 APL-2 - Drug Profile 60 AS-2521780 - Drug Profile 62 basiliximab biobetter - Drug Profile 63 BB-3 - Drug Profile 64 belimumab - Drug Profile 68 bleselumab - Drug Profile 74 BRN-1889 - Drug Profile 75 C1 esterase inhibitor (human) - Drug Profile 76 C1 esterase inhibitor (human) - Drug Profile 81 C1 esterase inhibitor (recombinant) - Drug Profile 83 Cardiotrophin-1 - Drug Profile 91 carfilzomib - Drug Profile 93 CB-2782 - Drug Profile 105 Cellgram for Kidney Transplantation - Drug Profile 106 Cellular Immunotherapy for Kidney Transplantation - Drug Profile 107 Cellular Immunotherapy for Kidney Transplantation - Drug Profile 108 Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile 109 CFZ-533 - Drug Profile 110 eculizumab - Drug Profile 112 EFFI-7H - Drug Profile 121 FCR-001 - Drug Profile 123 foralumab - Drug Profile 125 FR-104 - Drug Profile 126 FX-06 - Drug Profile 129 lefluonomide - Drug Profile 131 Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile 132 Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile 134 MRX-109 - Drug Profile 135 N-003 - Drug Profile 136 OPN-305 - Drug Profile 137 QPI-1002 - Drug Profile 139 Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 142 Renaparin - Drug Profile 146 rituximab - Drug Profile 147 Sanguinate - Drug Profile 152 tiomolibdate diammonium - Drug Profile 154 TNT-009 - Drug Profile 155 Kidney Transplant Rejection - Dormant Projects 157 Kidney Transplant Rejection - Discontinued Products 160 Kidney Transplant Rejection - Product Development Milestones 161 Featured News & Press Releases 161 Appendix 170 Methodology 170 Coverage 170 Secondary Research 170 Primary Research 170 Expert Panel Validation 170 Contact Us 170 Disclaimer 171
List of Tables
Number of Products under Development for Kidney Transplant Rejection, H2 2016 12 Number of Products under Development for Kidney Transplant Rejection - Comparative Analysis, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Number of Products under Development by Companies, H2 2016 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 17 Comparative Analysis by Clinical Stage Development, H2 2016 18 Comparative Analysis by Early Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2016 22 Kidney Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 23 Kidney Transplant Rejection - Pipeline by Amgen Inc., H2 2016 24 Kidney Transplant Rejection - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016 25 Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp., H2 2016 26 Kidney Transplant Rejection - Pipeline by Apellis Pharmaceuticals Inc, H2 2016 27 Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc., H2 2016 28 Kidney Transplant Rejection - Pipeline by Bio-inRen, H2 2016 29 Kidney Transplant Rejection - Pipeline by Biogen Inc, H2 2016 30 Kidney Transplant Rejection - Pipeline by Catalyst Biosciences, Inc., H2 2016 31 Kidney Transplant Rejection - Pipeline by Corline Biomedical AB, H2 2016 32 Kidney Transplant Rejection - Pipeline by CSL Limited, H2 2016 33 Kidney Transplant Rejection - Pipeline by Digna Biotech, S.L., H2 2016 34 Kidney Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H2 2016 35 Kidney Transplant Rejection - Pipeline by Grifols, S.A., H2 2016 36 Kidney Transplant Rejection - Pipeline by Hansa Medical AB, H2 2016 37 Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 38 Kidney Transplant Rejection - Pipeline by Mabtech Limited, H2 2016 39 Kidney Transplant Rejection - Pipeline by Magnus Life Ltd, H2 2016 40 Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG, H2 2016 41 Kidney Transplant Rejection - Pipeline by Novartis AG, H2 2016 42 Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Limited, H2 2016 43 Kidney Transplant Rejection - Pipeline by OSE Immunotherapeutics, H2 2016 44 Kidney Transplant Rejection - Pipeline by Pharmicell Co., Ltd., H2 2016 45 Kidney Transplant Rejection - Pipeline by Pharming Group N.V., H2 2016 46 Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 47 Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 48 Kidney Transplant Rejection - Pipeline by Shire Plc, H2 2016 49 Kidney Transplant Rejection - Pipeline by Tiziana Life Sciences Plc, H2 2016 50 Assessment by Monotherapy Products, H2 2016 51 Number of Products by Stage and Target, H2 2016 53 Number of Products by Stage and Mechanism of Action, H2 2016 55 Number of Products by Stage and Route of Administration, H2 2016 57 Number of Products by Stage and Molecule Type, H2 2016 59 Kidney Transplant Rejection - Dormant Projects, H2 2016 160 Kidney Transplant Rejection - Dormant Projects (Contd..1), H2 2016 161 Kidney Transplant Rejection - Dormant Projects (Contd..2), H2 2016 162 Kidney Transplant Rejection - Discontinued Products, H2 2016 163
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
